Nucleus RadioPharma, Inc. announced that it will issue 10,547,047 series A preferred shares at issue price of $5.8879 per share for the gross proceeds of $62,099,958.0313 in funding on September 15, 2023. The shares are convertible and non-redeemable. The shares will be convertible into common shares at a price of $5.8879 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
74.74 USD | -1.37% | -3.59% | -3.34% |
06-10 | GE HealthCare Reports Changes in Key Segments | MT |
06-05 | Transcript : GE HealthCare Technologies Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 10:00 AM |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.34% | 34.59B | |
+8.50% | 222B | |
+24.13% | 148B | |
+33.45% | 114B | |
+4.45% | 65.69B | |
+14.10% | 51.88B | |
+4.08% | 50.02B | |
-4.98% | 38.81B | |
+22.18% | 31.09B | |
+19.53% | 24.62B |
- Stock Market
- Equities
- GEHC Stock
- News GE HealthCare Technologies Inc.
- Nucleus RadioPharma, Inc. announced that it expects to receive $62.099958 million in funding